Wingate Wealth Advisors Inc. Buys New Shares in Johnson & Johnson (NYSE:JNJ)

Wingate Wealth Advisors Inc. purchased a new position in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, Holdings Channel reports. The firm purchased 1,612 shares of the company’s stock, valued at approximately $233,000.

A number of other large investors have also made changes to their positions in the stock. Savant Capital LLC raised its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Savant Capital LLC now owns 248,256 shares of the company’s stock valued at $35,903,000 after purchasing an additional 729 shares in the last quarter. Angeles Wealth Management LLC increased its holdings in Johnson & Johnson by 2.1% in the 4th quarter. Angeles Wealth Management LLC now owns 16,166 shares of the company’s stock valued at $2,338,000 after buying an additional 329 shares during the period. Tevis Investment Management raised its stake in shares of Johnson & Johnson by 2.1% in the 4th quarter. Tevis Investment Management now owns 17,692 shares of the company’s stock valued at $2,559,000 after buying an additional 358 shares in the last quarter. Legacy Financial Strategies LLC lifted its holdings in shares of Johnson & Johnson by 6.4% during the 4th quarter. Legacy Financial Strategies LLC now owns 4,073 shares of the company’s stock worth $587,000 after acquiring an additional 245 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $518,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Guggenheim raised their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Bank of America dropped their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $155.23 on Thursday. The stock’s fifty day moving average price is $147.48 and its two-hundred day moving average price is $156.01. The firm has a market cap of $373.73 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.